Pediatrics Book

Fluids, Electrolytes, and Nutrition

Hematology and Oncology

Miscellaneous

Neurology

Urology

http://www.fpnotebook.com/

PemolineAka: Cylert

Advertisement

  1. Indications
    1. Attention Deficit Hyperactivity Disorder (ADHD)
      1. Not recommended as first line agent
  2. Pharmacokinetics
    1. Onset: 2 hours
    2. Duration: 6 to 10 hours
    3. Steady state reached in 2 to 3 days
    4. Titrate dose every 3 to 4 weeks
  3. Dosing
    1. Range: 0.5 - 2.5 mg/kg/dose (Up to 112.5 mg/day)
    2. Start: 18.75 mg PO qAM
    3. Frequency: Once to twice daily
  4. Monitoring
    1. Alanine Aminotransferase (ALT)
      1. Obtain baseline
      2. Repeat testing every 2 weeks
    2. Symptom inquiry at every visit
      1. Anorexia
      2. Malaise
      3. Gastrointestinal symptoms
      4. Dark urine
  5. Precautions
    1. Informed consent from parents required prior to use
  6. Adverse Effects
    1. Hepatic failure of dysfunction
    2. Choreoathetoid movements
    3. Other adverse effects similar to Methylphenidate
  7. References
    1. (1996) Pediatrics 98:301
    2. Andesman (1999) Pediatr Clin North Am 46:945
    3. Bennett (1999) Pediatr Clin North Am 46:929
    4. Challman (2000) Mayo Clin Proc 75:711

Pemoline (C0030800)

Definition (MSH)A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
Definition (NCI)An oxazolidine compound with central nervous system (CNS) stimulant property. Although pemoline has pharmacological activity similar to other CNS stimulants, the exact mechanism and site of action are unknown. This agent has minimal sympathomimetic properties, but animal studies indicate it may work through dopaminergic mechanisms. Pemoline has been withdrawn from the U.S. market because of the agent's association with life threatening hepatic failure.
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD010389
English2-Imino-4-keto-5-phenyltetrahydrooxazole, 5-Phenylisohydantion, Pemoline, PEMOLINE PREPARATION, Phenoxazole, Phenylisohydantoin, PIO
Spanishfenilisohidantoina, pemolina
Parent ConceptsOxazoles (C0030004), Central Nervous System Stimulants (C0002763), Other central nervous system stimulants (C0731742), Drug allergen (C1320237), Non-amphetamines (C1579270)
SourcesAOD, CSP, LNC, MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Cylert (C0719594)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD010389
EnglishAbbott Brand of Pemoline, Cylert
SourcesMSH, NCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree